MSLE Satellos Bioscience Inc.

NEUTRAL Impact: 2/10 6-K
Horizon weeks Filed May 20, 2026 Processed 25d 20h ago SEC 0001171843-26-003561
Notable filing: 6-K
Latest settled — T+5d
MSLE ▼ -4.42% at T+5d
NEUTRAL call ✗ call lost -4.42% · α vs SPY -6.22% · entry $7.36 → $7.03
Next anchor: T+20d in 3d
Last close $5.75 (close Jun 12) · -21.82% from $7.36 entry
Entry anchored
May 20, 2026
via day open
T+1d
-2.92%
call -2.92% · α -3.12%
$7.14
settled 25d ago
T+5d
-4.42%
call -4.42% · α -6.22%
$7.03
settled 18d ago
T+20d
call — · α —
in 3d
T+60d
call — · α —
in 2mo

Price Chart

Loading chart...

Executive Summary

Satellos Bioscience Inc. filed its management information circular and proxy materials for the June 17, 2026 annual general meeting. The filing covers routine matters: election of nine director nominees, appointment of PricewaterhouseCoopers as auditors, and receipt of FY2025 audited financial statements. No material financial data, business updates, or strategic changes are disclosed — this is a standard annual meeting solicitation with no actionable trading implications.

Actionable Insight

No trading action warranted. This is a standard annual meeting proxy filing with no earnings, guidance, or material corporate developments. Monitor for Phase 2 clinical data readouts for SAT-3247 in Duchenne muscular dystrophy as the next potential catalyst.

Key Facts

  • Annual general meeting scheduled for June 17, 2026, in virtual-only format
  • Shareholders to vote on election of 9 director nominees and appointment of PwC as auditors
  • As of May 14, 2026, 20,831,190 common shares outstanding (post-12:1 consolidation on Jan 27, 2026)
  • No 10%+ beneficial holders identified
  • Equity Incentive Plan has 358,116 shares available for future grants (~1.7% of outstanding)
  • FY2025 audited financial statements to be presented but no shareholder vote required

Financial Impact

No financial impact — routine proxy solicitation with no material business or financial disclosures

Risk Factors

  • No material risks disclosed beyond standard forward-looking statement cautionary language

Market Snapshot

Exchange
Nasdaq
Sector
Pharmaceutical Preparations
Analyst Consensus
89% bullish (9 analysts)

Documents Analyzed

This report is based on 8 SEC documents filed with EDGAR.

DocumentAccession Number
6-K Filing (Primary)0001171843-26-003561
Exhibit: exh_993.htm0001171843-26-003561
Exhibit: exh_992.htm0001171843-26-003561
Exhibit: exh_994.htm0001171843-26-003561
Document: f6k_051926.htm0001171843-26-003561
Document: 0001171843-26-003561-index-headers.html0001171843-26-003561
Document: 0001171843-26-003561-index.html0001171843-26-003561
Document: 0001171843-26-003561.txt0001171843-26-003561
5 reports for MSLE
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for MSLE — sortable, filterable
Type Now
May 20, 2026
25d ago
6-K
NEUTRAL ★ 2/10
$7.36 $7.03▼ −4.42%▼ −6.22%$5.75 (−21.82%)
May 15, 2026
4w ago
6-K
NEUTRAL ★ 5/10
$7.01 $6.75▼ −3.71%▼ −4.67%$5.75 (−17.97%)
May 15, 2026
4w ago
Press Release
NEUTRAL ★ 5/10
$7.01 $6.75▼ −3.71%▼ −4.67%$5.75 (−17.97%)
Apr 9, 2026
9w ago
6-K
NEUTRAL ★ 3/10
$6.20 $8.59▲ +38.55%▲ +35.36%$5.75 (−7.26%)
Mar 27, 2026
11w ago
6-K
BULLISH ★ 8/10
$6.19 $5.65▼ −8.72%▼ −12.59%$5.75 (−7.11%)
Showing 5 of 5

US Market Status

Market Closed — Opens in 5h 11m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access